Coming soon... miRpredX 31-3p - the 1st positive theranostic test for metastatic colorectal cancer

The miRpredX 31-3p test predicts clinical response to anti-EGFR therapy in RAS wild type patients with metastatic colorectal cancer assisting clinicians to identify the most appropriate therapeutic strategy when combining information on miRNA miR-31-3p expression with other molecular and patient factors which influence patient outcomes.

The miRpredX 31-3p test enables clinicians to identify patients for which first line anti-EGFR treatment will be of greater clinical benefit versus anti-VEGF therapy or when second or further lines of treatment with anti-EGFR therapy is beneficial to patients.